PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
- PMID: 15207817
- DOI: 10.1016/j.cytogfr.2004.03.002
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
Abstract
PDGFs and their cognate tyrosine kinase alpha- and beta-receptors are involved in multiple tumor-associated processes including autocrine growth stimulation of tumor cells, stimulation of tumor angiogenesis and recruitment and regulation of tumor fibroblasts. The recent development of clinically useful PDGF antagonists, like STI571/Glivec, has increased the interest in PDGF receptors as cancer drug targets. Autocrine PDGF receptor signaling occurs in certain malignancies characterized by mutational activation of PDGF or PDGF receptors, for instance, dermatofibrosaracoma protuberans, gastrointestinal stromal tumors, and hypereosinophilic syndrome. The roles of PDGF in regulation of tumor angiogenesis and tumor fibroblasts are more general, and probably occur in most common solid tumors. Concerning tumor angiogenesis recent studies have predominantly focused on the importance of PDGF receptor signaling for tumor pericyte recruitment. PDGF receptors in the tumor stroma have also attracted attention as interesting drug targets because of their function as regulators of tumor interstitial fluid pressure, tumor transvascular transport and tumor drug uptake. In summary, the improved understanding of the role of PDGF signaling in tumor biology, and the introduction of PDGF antagonists, has set the stage for a continued development of PDGF antagonists as novel cancer drugs.
Similar articles
-
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.Cancer Res. 2002 Oct 1;62(19):5476-84. Cancer Res. 2002. PMID: 12359756
-
Platelet-derived growth factor receptors: a therapeutic target in solid tumors.Semin Oncol. 2001 Oct;28(5 Suppl 17):27-33. Semin Oncol. 2001. PMID: 11740804 Review.
-
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.Cancer Res. 2001 Aug 1;61(15):5778-83. Cancer Res. 2001. PMID: 11479215
-
PDGF receptors as targets in tumor treatment.Adv Cancer Res. 2007;97:247-74. doi: 10.1016/S0065-230X(06)97011-0. Adv Cancer Res. 2007. PMID: 17419949 Review.
-
Platelet-derived growth factor (PDGF) and glial tumorigenesis.Cancer Lett. 2006 Feb 8;232(2):139-47. doi: 10.1016/j.canlet.2005.02.002. Epub 2005 Aug 31. Cancer Lett. 2006. PMID: 16139423 Review.
Cited by
-
CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma.PLoS One. 2011;6(12):e28842. doi: 10.1371/journal.pone.0028842. Epub 2011 Dec 20. PLoS One. 2011. PMID: 22205974 Free PMC article.
-
Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era.Biomedicines. 2022 Aug 9;10(8):1927. doi: 10.3390/biomedicines10081927. Biomedicines. 2022. PMID: 36009473 Free PMC article. Review.
-
Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors.BMC Cancer. 2011 Nov 9;11:480. doi: 10.1186/1471-2407-11-480. BMC Cancer. 2011. PMID: 22070644 Free PMC article.
-
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.Cancer Chemother Pharmacol. 2014 Nov;74(5):917-25. doi: 10.1007/s00280-014-2567-9. Epub 2014 Aug 23. Cancer Chemother Pharmacol. 2014. PMID: 25149088 Free PMC article. Clinical Trial.
-
The regulatory roles of microRNA-146b-5p and its target platelet-derived growth factor receptor α (PDGFRA) in erythropoiesis and megakaryocytopoiesis.J Biol Chem. 2014 Aug 15;289(33):22600-22613. doi: 10.1074/jbc.M114.547380. Epub 2014 Jun 30. J Biol Chem. 2014. PMID: 24982425 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases